Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Zhongguo Shi Yan Xue Ye Xue Za Zhi|October 10, 2021
[Cdc37 Expression in Multiple Myeloma and Its Role in Cell Proliferation]Mei-Rong Zang, Lan-Ting Liu, Shu-Hui Deng, et al.Zhongguo Shi Yan Xue Ye Xue Za Zhi|August 18, 2016
[Role of miR137-MITF in Prognostic Analysis of Multiple Myeloma]Shuai-Shuai Zhang, Yan Xu, Shu-Hui Deng, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 11, 2008
[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients]Shu-Hui Deng, Yan Xu, Yu-Jie Mai, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 27, 2008
[Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma]Ya-fei Wang, Shu-hui Deng, Tong Wu, et al.Zhongguo Shi Yan Xue Ye Xue Za Zhi|June 29, 2012
[Expression of B7-H1 gene in leukemia cells and its clinical significance]Xin Li, Wan-Jun Sun, Yan Xu, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 15, 2013
[Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy]Yan Xu, Gang An, Shu-hui Deng, et al.Zhongguo Shi Yan Xue Ye Xue Za Zhi|December 28, 2013
[Prognostic value of serum IL-6 in patients with multiple myeloma]Li-Jie Xing, Yan Xu, Gan An, et al.Zhonghua Yi Xue Za Zhi|September 11, 2007
[Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case]Shu-hui Deng, Yan Xu, Ya-fei Wang, et al.Zhongguo Shi Yan Xue Ye Xue Za Zhi|June 18, 2019
[Clinical Analysis of B-CLPD with Cytopemia as the Predominant Characteristic]Rui Lu, Zeng-Jun Li, Gang An, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 20, 2007
[The analysis of prognostic variables in 123 patients with multiple myeloma]Yan Xu, Shu-hui Deng, Yu-jie Mai, et al.Pageof 2